The levels of EZH2 and other PRC2 components have been reported to be high in SCLC (Sato et al., 2013), and recently a therapeutic strategy involving chemotherapy combined with EZH2 inhibitors was suggested to prevent chemotherapy resistance of SCLC (Gardner et al., 2017). This evidence concerns the gene EZH2 and small cell lung carcinoma.